Pubmed Biomarker Relation P-value Description
27898420 BANCR p=0.010 The level of BANCR expression was correlated with FIGO stage
30684972 RRBP1 high stage p=0.003 High levels of expression of RRBP1 were strongly correlated with high FIGO stage
17108150 ephrinB2/EphB4 stages p<0.01 Both the histoscores and mRNA levels of ephrinB2 significantly increased with clinical stages (I < II < III
17068614 ERalpha stage I p=0.005 The expression rate of ERalpha in patients with FIGO stage I endometrial carcinoma was more than that in stage II-IV
17068614 ERalpha stage I p=0.007 The expression rate of ERRalpha in endometrial carcinoma patients at FIGO stage I was lower than that at stages II-IV
17065588 versican advanced-stage p=0.010 Stromal versican expression was significantly higher in the advanced-stage
16888409 TADG-14/KLK8 stage I p=0.0433 hK8 expression was significantly higher in stage I
16681769 ERRalpha and ERRgamma stage p=0.019 Expression of ERRalpha mRNA was positively correlated with FIGO stage
16445666 cyclin H stage The expression of cyclin H was correlated with clinical stage
16311121 Aurora B survival/advanced stage p=.0452 Multivariate analysis using the 3 variables (stage, grade, and Aurora B) showed that independent prognostic indicators for poorer survival were advanced stages
16014121 c-FLIP stage p<0.05 Multivariate analysis of variance also confirmed the association of c-FLIP with clinical stage
16014121 c-FLIP p<0.05 The expression levels of c-FLIP protein were significantly higher in clinical stage III/IV than in stage I/II. Multivariate analysis of variance confirmed that the expression levels of c-FLIP were indeed associated with clinical stage.
30556848 LncRNA FER1L4 stage p=0.006 Low expression of FER1L4 was significantly correlated with FIGO stages
15363194 P53 stage p<0.005 P53 expression was associated with surgical pathologic stage, and depth of myometrial invasion in EC
15363194 C-erbB-2 stage I p<0.001 C-erbB-2 expression was associated with surgical pathologic stage
15218296 placental leucine aminopeptidase stage p=0.02 There was a positive correlation between the expression of P-LAP and surgical stage of the disease
15025952 cFLIP stage p<0.05 cFLIP expression was also significantly associated with clinical stage
14764041 c-myc protein stage p<0.0001 By multivariate analysis, positive cytoplasmic c-myc staining with FIGO stage shown to be independent prognostic indicators predictive of survival.
14629267 CD105/endoglin-MVD stage p=0.03 Tumours within the two groups defined by the upper and lower quartiles for CD105/endoglin-MVD were both significantly more often metastatic (FIGO-stage III/IV
12866577 HER-2:CEP17 ratio stage p=0.021 HER-2 amplification was significantly correlated with tumor stage
12819391 endoglin (CD105) stage p<0.001 Only endoglin counts correlated significantly with tumor stage
12798703 Elf-1 stage p<0.01 Scoring on the basis of the percentage of nuclear-positive cells indicated that nuclear Elf-1 expression was significantly associated with clinical stage
12556100 DNA topoisomerase II-alpha (Ki-S1) Stage p<or=0.05 Topoisomerase II-alpha (Ki-S1) staining was significantly elevated in advanced (Stage II, III, IV) as opposed to early (Stage I) carcinomas
30377136 MMP20 stage p=0.014 An elevated MMP20 protein expression was positively associated with FIGO stage of endometrial carcinoma
12525874 CaMKIV stage p<0.01 CaMKIV expression was significantly associated with clinical stage (stage I and II versus stage III and IV
12130664 UPAR stage p<0.0001 UPAR protein expression highly correlated with stage of disease(ungrouped Spearman correlation = 0.625)
11504312 endostatin discrimination/stage Serum endostatin levels in endometrial hyperplasia (149+/-19 ng/ml), endometrial cancer stages I (320+/-41), II (644+/-86) and stage III-IV (1253+/-114) were also significantly higher than the mean for controls (13+/-2.4).
11504312 VEGF discrimination/stage Serum VEGF levels in endometrial hyperplasia (142+/-18 ng/ml, mean +/- SE) and endometrial cancer stages I (291+/-22), II (623+/-68) and stage III-IV (1527+/-119) were significantly higher than the mean for controls (12+/-1.6).
11431715 telomerase stage p=.01 Telomerase activity was detected in 50 of 53 ECs (94%). Its levels correlated significantly with FIGO stage
11161861 VEGF advanced stage p=0.03 Higher cytosol VEGF concentrations were noted in tumors with advanced stage (more than stage I) (917 versus 125 pg/mg)
11161861 MVD advanced stage p=0.008 Higher cytosol MVD values were noted in tumors with advanced stage ( 94.1 +/- 37.8 versus 60.8 +/- 38.9)
11078809 human telomerase reverse transcriptase stage p<0.05 RTA was significantly higher at an advanced surgical stage (FIGO II, III or IV) than at an early stage (FIGO 0 or I) (52.4 vs. 20.4, ), but other clinical factors showed no relationship with TERT and RTA values.
10999747 Serum soluble fas stage p<0.0001 Levels of serum sFas in patients with advanced cancer (FIGO stages III and IV) significantly exceeded those in patients with localized cancer (FIGO stages I and II) or those in normal control subjects
9829742 Ki-67 stage p=0.0004 The expression of Ki-67 was significantly associated with International Federation of Gynecology and Obstetrics (FIGO) stage
30134343 PD-L1 stage I p=0.004 Negative PD-L1 scores for FIGO stage 1 patients were seen to be higher than the other stages and scores, which was statistically significant
9648591 PR stage p=0.001 PR immunohistochemistry of endometrial carcinoma was statistically correlated with the International Federation of Gynecology and Obstetrics (FIGO) stage (I, II vs III, IV
9596268 vimentin stage p<.001 Vimentin positivity were associated with low-stage tumors.
9038731 CA 72-4 stage p<0.05 There was a significant correlation between CA72-4 positivity and surgical stage of the disease
8909315 S-phase fraction (SPF) advanced stage p<0.0001 Mean SPF was high in advanced stages and strongly associated with histopathologic subtype
8909315 S-phase fraction (SPF) advanced stage Mean SPF was high in advanced stages and strongly associated with ploidy.
1427403 Plasminogen activator inhibitor-type 2 (PAI-2) stage p<0.05 Levels of endometrial PAI-2 were higher in stages IC or greater compared to those in stages IA and 1B cancers
35241527 VEGFR2 T1 stage The positive correlation between HER2 and VEFR2 expression was statistically significant in T1 stage.
36123916 APOE stage The expression level of APOE in endometrial cancer was correlated with histological grade, lymph node metastasis, and FIGO stage.
36721236 SLERT P = 0.002 SLERT was significantly correlated with FIGO stage
36396713 CA125 The largest increase in risk for patients having stage I/II/III disease was 52% greater (1.52-fold risk) while largest increase in risk for patients having stage III/IV disease was 67% greater (1.67-fold risk), both at CA125 ≥ 222U/ml.
30134343 PD-L1 stage p=0.046 A difference was also observed concerning the FIGO stage in PD-L1 immune cells
34282107 TAMs P=0.004 The counts of margin TAMs was significantly correlated with FIGO stage.
36251972 p53 P <0.001 Abnormal p53 IHC expression was expressed in 33.3% of the cases and significantly associated with the tumor grade, myometrial invasion (MI), lymphovascular invasion (LVSI), nodal metastasis, and FIGO stage, and the advanced European Society for Medical Oncology (ESMO) risk groups
36251972 Pirh2 P =0.024 High IHC Pirh2 expression was noted in 58.3% of the cases, and significantly associated with FIGO stage
36251972 L1CAM P <0.001 Positive L1CAM immunoexpression was noted in 26.7% and was significantly associated with FIGO stage
28383326 neopterin P < 0.001 Increased urinary neopterin levels were observed in patients with endometrial cancer (P < 0.001), and the difference in the urinary neopterin levels between low and high stages of endometrial cancer was significant (P < 0.01; stage I-II vs stage III-IV, respectively).
29984790 c-Myc stage p<0.05 MACC1/c-Myc expression was correlated with TNM stage,
29984790 MACC1/c-Myc stage p<0.05 MACC1/c-Myc expression level was correlated with TNM stage
29848072 miR-29b stage p<0.05 miR-29b expression in the peripheral blood was correlated with FIGO staging
29526558 TRIM44 stage p<0.05 TRIM44 overexpression was associated with FIGO
29114696 cancer antigen 15-3 levels advanced stage (≥Stage II) p<0.05 Serum cancer antigen 15-3 levels were significantly higher in patients with advanced (≥Stage II) disease
35729354 SLeX p=0.006 High expression of SLeX was correlated to low FIGO-stage
28980703 IRAK1 higher tumor stage p<0.05 Fisher’s exact test indicated that IRAK1 expression level was significantly correlated with higher tumor stage
28965628 cyclin D1 stage III and IV p=0.029 Stage of tumor was significantly associated with cyclin D1 immunohistochemical staining，proportion of stage III and IV are higher in negative cyclin D1 immunostaining.
28800309 CA125 advanced stage According to the ROC curve, the suitable cut-off value for CA125 in advanced stage (sensitivity = 73%, specificity = 55%, positive predictive value = 18%, negative predictive value = 78%) was 20 u/ml.
28624692 CA125 stage(>IB) p<0.004 We observed significantly higher CA125 concentrations in patients with higher levels of clinical stages when compared to patients in the FIGO stages I-IB,
28618925 DJ-1 advanced stage (III/IV p≤0.05 DJ-1 serum levels were significantly higher in the advanced stage (III/IV) than in early stage (I/II;
28453461 SerpinE2 advanced stage p=0.020 High SerpinE2 expression was correlated with advanced TNM stage
28401338 HE4 stage p=0.001 Serum HE4 concentration is significantly associated with stage of disease
28383326 neopterin stage p<0.01 The difference in the urinary neopterin levels between low and high stages of endometrial cancer was significant (stage I–II VS stage III–IV)
28215640 galectin-3 stage p=0.016 Stage was significantly associated with galectin-3 immunoreactivity
28178620 miR-944 stage p<0.05 Tumor tissues arising from patients with advanced FIGO stages showed significant higher expressions of miR-944
34339705 SOX17 low stage p=0.001 SOX17 positive expression was positively correlated with low stage
28098927 HE4 stage p<0.001 Serum HE4 levels ere significantly higher in patients with stage II-III as compared to stage I EC and non-malignant endometrial pathologies
27873306 ALCAM stage In multivariate analysis, ALCAM-positivity was an independent prognostic factor in early stage disease(HR 6.027; 95% CI 1.41-25.74)
27648714 L1CAM stage L1CAM positivity was associated with high stage (I vs II-IV) (odds ratio [OR], 2.3)
27540975 UCA1 advanced stage p=0.031 High UCA1 expression was observed to be closely correlated with advanced TNM stage
27512000 GGT stage II EAC p<0.001 After stratification of the cancer cases according to FIGO staging, the lowest median apical GGT expression levels were in II EAC (0.0, S.E.M. = 0.64) tumours compared with IA (4.0, S.E.M. = 0.47) tumours, specimen and normal endometrium (2.0, S.E.M. = 2.8)
27340318 IL-31 stage p =0.024 It revealed that serum IL-31 was related to tumor stages
27340318 IL-33 stage p=0.035 Serum IL-33 was close to the disease process: tumor stages
27153547 ERRα advanced stage p<0.01 ERRα was expressed in all examined tissues and the elevated expression levels of ERRα were associated with advanced clinical stages
27079858 clusterin stage I p=0.002 Positive clusterin immunostaining was found more frequent in stage I endometrial carcinomas, showing significant statistical association
27003026 SLUG stages III/IV/RFS p=0.0146 High SLUG expression was associated with worse recurrence-free survival (RFS) in the patients in patients at stages III/IV
33635467 BMP-10 FIGO stage p=0.001 BMP-10 expression was significantly correlated with International Federation of Gynecology and Obstetrics (FIGO) stage
26985869 MIF early stages p=0.036 MIF protein expression was significantly lower in endometrial carcinoma with early FIGO stages
26985869 c-erbB-2 early stages p=0.036 C‑erbB‑2 expression was significantly lower in endometrial carcinoma with early FIGO stages
26985869 MIF stages I–II p=0.01 MIF protein had a higher expression in tumors at stages I–II (χ2=6.632)
26985869 c-erbB-2 stages III–IV p=0.024 C-erbB-2 protein expression was higher in tumors at stages III–IV (χ2=4.800)
26985869 MIF early stages p=0.001 MIF mRNA overexpression appeared to correlate with lower aggressiveness: It was significantly associated with early FIGO stages
26985869 c-erbB-2 stages III–IV p=0.630 The analysis demonstrated that the levels of c-erbB-2 mRNA were higher in FIGO stages III–IV compared with early FIGO stages
26763250 POLE exonuclease domain mutations (EDM) stage p<0.001 The majority of POLE positive tumours were Stage I (95%), two Stage II-III, and no Stage IV tumours; compared to tumors without POLE mutations in which 248 (68%) were Stage I, and 116 (32%) Stage II-IV
26608413 CD133 stage I-II p=0.021 CD133 was more expressed by early stage tumor (FIGO I-II) compared with those having FIGO III to IV stage disease
26607777 HE-4 advanced stages p=0.004 Serum HE-4 levels were significantly higher in advanced stages
26362938 ANXA2 advanced stages( stage III–IV) p<0.05 The high expression rate of ANXA2 in stage III–IV endometrial carcinoma patients was 91.7 % (22/24), which was significantly higher than stage I–II patients (55.0 % [33/60]
33235117 TWIST1 FIGO stage p=.004 Increased TWIST1 expression was significantly associated with FIGO stage
26362938 HE4 advanced stages( stage III–IV) p<0.05 The high expression rate of HE4 in stage III–IV endometrial carcinoma was 66.7 % (16/24), which was significantly higher than stage I–II (36.7 % [22/60]
26350184 TATI stage IIIB vs stage I (Kruskal-Wallisp=0.0446 Mean TATI concentrations were significantly higher in patients with clinically advanced disease (stage IIIB) than patients at stage I
26308378 ATAD2 advanced stages p<0.001 Comparing ATAD2 expression with clinical and histopathological variables for aggressive endometrial cancer, we find a highly significant association between high ATAD2 expression and high FIGO (International Federation of Gynecology and Obstetrics) stage
26260911 Metabolic syndrome stage p=0.021 MS was closely related to stage
26245990 CDC20 advanced stages p=0.047 High CDC20 expression and advanced tumor stage in carcinoma of endometrium
26191146 Musashi-1 protein advanced stages(stage II-III vs stage I ) p=0.043 Musashi-1 expression was also higher in stage II-III group than in stage I group
26166558 LSD1 advanced stages p=0.035 LSD1 overexpression was significantly associated with the advanced extent of EEA, such as a high FIGO stage
26028082 LVSI advanced stages p=0.025 Lympho-vascular space invasion (LVSI) showed predictivity for advanced stage uterine papillary tumor.
25874492 Sam68 stage p=0.039 The high expression of Sam68 was associated with FIGO stage
25355598 HABP1 advanced stage p=0.019 High HABP1 expression was significantly associated with advanced International Federation of Gynecology and Obstetrics stage
33156532 HE4 advanced stage p=0.003 A statistically significant association was found between the preoperative HE4 value and late-stage disease
25315186 cyclin B advanced stage Cyclin B expression correlated with advanced stage
24972085 Yes-associated protein (YAP) stage p=0.028 Increased nuclear YAP expression was significantly associated with stage
24930886 KPNA2 higher tumou stage p=0.027 KPNA2 expression was significantly up-regulated in human endometrial carcinomas and associated with higher FIGO stage
24853175 HSF1 aggressive disease p<0.02 High expression of HSF1 protein in endometrial carcinoma is significantly associated with aggressive disease
24692842 HDGF stage p=0.032 High nuclear expression of HDGF was positively correlated with FIGO stage
24692842 HDGF stage III p=0.012 High HDGF protein expression was significantly associated with FIGO stage III
24346847 Maspin less aggressive Maspin expression were generally correlates with a less aggressive behavior, is significantly higher in atypical hyperplasia and in endometrial endometrioid adenocarcinoma
24211402 Serum HE4 stage III and IV p<0.001 Median CA125 and HE4 levels were higher in stage III and IV tumours
23818363 hPEBP4 stage p=0.0247 Expression of hPEBP4 was significantly higher with progressing stage
23700142 API stage I p=0.0002 In stage I cases, API showed significantly higher positivity than that of CA125
33156532 HE4 advanced stage p=0.001 preoperative HE4 cut-off VS advance stage of disease (FIGO stage III-IV) (HR=0.835 ;95% confidence interval [CI] 0.71–0.95)
23438672 Visfatin advanced FIGO stage p=0.016 High visfatin expression in EC tissues was significantly associated with advanced FIGO stage
23372184 hypoxia-inducible factor 1α and TWIST aggressive disease p<0.01 Among various clinical parameters, the expression of hypoxia-inducible factor 1α and TWIST was strikingly elevated with aggressive tumor characteristics, including higher pathologic grade, deep myometrial invasion and lymph node involvement(95% confidence interval [CI] 0.71–0.95).
23334889 Bub1 stage p=0.009 The lower positive of Bub1 was related to clinical stage of endometrial cancer
23200913 GRP78 advanced-stage disease p=0.007 High visceral adipocyte GRP78 expression positively correlated with advanced-stage disease
23114646 EMT stage p<0.01 EMT status, which was represented by both reduced E-cadherin and nuclear expression of Snail, was significantly associated with FIGO stage.
22889453 HSPA5 stage p=0.003 The positive rate of HSPA5in stages Ia, Ib and II-IV EC samples were 54.4%(43/79), 76.5% (13/17) and 91.3% (21/23),
22617129 bFGF advanced stage p=0.008 Tumour bFGF was significantly associated with advanced stage
22412054 podocalyxin stage p=0.0062 Podocalyxin expression was correlated with FIGO stage
22412054 pEzrin stage p=0.0231 pEzrin expression was associated with FIGO stage
22198340 tumor budding (TB) advanced stage p=0.032 The high-grade TB was significantly higher in patients with advanced stage
33059604 MCM5 stage Overall sensitivity for endometrial cancer was 87.8% and remained high for low stage disease(95% CI: 68.3–96.1%).
22015044 Synuclein-γ (SNCG) protein advanced tumor stage p=0.032 There was a strong association between SNCG+ and advanced tumor stage
22008707 ADCmin stage p=0.001 There were significant correlations between the ADCmin of the primary tumor and the FIGO stage
21764107 SUVmax stage p=0.030 There were significant correlations between the SUVmax of the primary tumor and the FIGO stage
21720250 HE4 stage IA Levels of serum HE4 greater than 70 pM displayed a sensitivity of 94% and a negative predictive value of 97% in identifying stage IA (<50% myometrial invasion) versus stage IB (≥ 50% myometrial invasion) tumors
21720250 HE4 advanced tumors Levels of serum HE4 greater than 70 pM displayed a sensitivity of 82% and negative predictive value of 82% versus all more advanced tumors.
21616994 GDF-15 stage III/IV p≤0.001 High plasma GDF-15 was significantly associated with International Federation of Gynecology and Obstetrics (FIGO) stage III/IV disease,
21176560 Hsa-miR-155 tage p<0.05 The expressions were (2.1 ± 0.4) and (5.6 ± 0.8) times in stage I - II and III - IV endometrial cancer, respectively, in which there were significant difference
21103625 MVD stage MVD counts of patients with stage I EC was lower as compared with stage II + III patients.
19509570 p53 stage p=0.006 P53 expression was related to a high stage of disease
19424619 DKK1 stage p<0.01 DKK1 expression level in EC at clinical stage I was significantly higher than those at stage II, III and IV
32433831 COX-2 stage p<.001 Positive expression of COX-2 was found to be related to more advanced and aggressive clinical stage of disease (stage I: positivity 0.0%, stage II: 30.8%, stage III: 57.9%, and stage IV: 73.3%)
18349274 Prostate-specific membrane antigen stage I p=0.046 Higher PSMA mRNA levels were associated with stage I
18313673 aquaporin-1 (AQP1) stage p<0.01 The AQP1/IMD ratio was significantly higher for stage III–IV than for stage I/II lesions
18289648 TAMs stage p=0.033 Margin TAMs were significantly associated with FIGO stage
18055714 CRP stage p=.01 Serum CRP levels were associated with tumor stage
17527071 MSI stage p=0.018 The MSI-high phenotype was related with the presence of the higher clinical stages
17504383 PTEN stage p=0.002 PTEN positivity was correlated with decreased stage
17504383 beta-catenin stage p=0.002 Positive beta-catenin expression was significantly associated with decreased stage
17504383 p53 increased stage p<0.0001 Positive staining of p53 was significantly correlated with increased stage
17260229 CA-125 advanced-stage p<0.001 Elevated serum CA-125 levels were significantly correlated with advanced-stage disease
17128692 body mass index (BMI) high stage p=0.04 Lower BMI was associated with high stage

Institutes for Systems Genetics, West China Hospital
     Copyright @ 2023 ISG. All Rights Reserved.